NDAORALTABLET
Approved
Jul 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
UREX (methenamine hippurate) by Gen Pharmaceuticals is clinical pharmacology methenamine hippurate is readily absorbed from the gi tract. First approved in 1967.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UREX (methenamine hippurate) is an oral antimicrobial tablet approved in 1967 for urinary tract infections. It works by converting to formaldehyde in acidic urine, which exhibits broad-spectrum bactericidal activity without resistance development. The drug distributes minimally systemically and is excreted primarily unchanged in urine within 24 hours.
LOE Approaching
As a 57-year-old product approaching loss of exclusivity with low commercial pressure (30% competitive intensity), the brand team is likely small and focused on maintenance rather than growth activities.
Mechanism of Action
CLINICAL PHARMACOLOGY Methenamine hippurate is readily absorbed from the GI tract. Methenamine distributes widely into body fluids, but very little is hydrolyzed prior to excretion in the kidney and thus has minimal systemic toxic potential. Within one-half hour after a single 1 g dose of a…
Indications
Worked on UREX at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.